查找临床试验
已按「骨髓增生异常综合征」检索，对应国际通用词 myelodysplastic syndrome
共找到 12 项正在招募的试验（在欧美日韩等发达国家设有中心）
数据更新于 10:03，每 5 分钟自动同步A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
United States
年龄 18 Years – 不限
M.D. Anderson Cancer Center
Trial of 2 Step ATG for Acute GVHD Prevention Post Myeloablative Allogeneic Stem Cell Transplant
United States
年龄 18 Years – 60 Years
University of Alabama at Birmingham
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
United States
年龄 2 Years – 75 Years
Masonic Cancer Center, University of Minnesota
Axatilimab With or Without Azacitidine for the Treatment of Patients With Advanced Phase Myeloproliferative Neoplasms, Myeloproliferative Neoplasm/Myelodysplastic Syndrome Overlap or High Risk Chronic Myelomonocytic Leukemia
United States
年龄 18 Years – 不限
Uma Borate
Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
United States
年龄 18 Years – 不限
National Cancer Institute (NCI)
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
United States
年龄 18 Years – 不限
Hannah Choe, MD
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
United States
年龄 18 Years – 70 Years
City of Hope Medical Center
Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
United States、Canada、France、Spain
年龄 18 Years – 不限
Bristol-Myers Squibb
Danicopan PMS in Korea
South Korea
年龄 不限 – 不限
AstraZeneca
A Post-Marketing Surveillance Study to Assess Safety of Luspatercept in Korean Patients With Myelodysplastic Syndrome or β-thalassemia
South Korea
年龄 19 Years – 不限
Bristol-Myers Squibb
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
United States、France
年龄 18 Years – 不限
Institut de Recherches Internationales Servier
A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia
United States
年龄 1 Month – 21 Years
Therapeutic Advances in Childhood Leukemia Consortium